Latest Strategy News

Warriedar Resources has nearly doubled its gold resource at the Ricciardo Project to 947.5 koz and uncovered promising antimony mineralisation, backed by strong metallurgical test results and a recent A$9.55 million capital raise.

Codeifai Limited has terminated its exclusive licence with MIT and launched a strategic review of its material science division, signaling a decisive pivot towards digital and AI-driven brand solutions.

Magnum Mining and Exploration Limited reported a net cash outflow of $87.68k for Q4 2024, ending the quarter with $332.81k in cash and a substantial $11 million in unused financing facilities.

Magnum Mining and Exploration Limited moves forward with acquiring two promising rare earth element projects in Brazil while progressing negotiations on a green pig iron venture in Saudi Arabia.

Eclipse Metals Ltd reports significant progress in its Greenland rare earth projects, including access to historic drill cores and positive resource estimates, while advancing towards mining licenses and applying for EU strategic funding.

Zenith Minerals reported a 40% increase in its Dulcie Far North gold resource and secured A$2.48 million in new funding, positioning the company for aggressive exploration across its Australian gold and lithium projects.

Beam Dental Bidco Pty Ltd has extended its off-market takeover offer for Pacific Smiles Group Limited, pushing the closing date to 11 February 2025. This move signals continued strategic interest and keeps the acquisition prospects open.

A1 Investments & Resources Ltd reports a modest cash outflow for the June 2024 quarter while actively pursuing acquisitions and planning convertible note funding to support growth.

Haranga Resources reports progress in its uranium and gold projects in Senegal, securing $500,000 in convertible loan funding to support upcoming drilling programs and exploration activities.

DXN Limited reported a robust 58.1% revenue increase to $4.8 million in Q2 FY25, underpinned by strategic capital raising and new product innovation targeting AI infrastructure. The company is advancing key mining and telecom projects while streamlining operations to support its ambitious $16 million revenue guidance for FY25.

Paradigm Biopharmaceuticals has secured FDA clearance for its phase 3 knee osteoarthritis trial and raised $16 million to fund its next clinical steps, positioning the company for a pivotal year ahead.

Impact Minerals Limited reported its December 2024 quarterly cash flow, revealing ongoing exploration expenditures and a significant $2.87 million grant to commercialise its High Purity Alumina process at Lake Hope.